文献速递乳腺癌支持与姑息治疗

芳香化酶抑制剂相关关节痛的老化感知与依从性

Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
PubMed 文献 · Eur J Cancer · 2018-01-09

该前瞻性队列研究纳入509例I-III期乳腺癌 survivor,在AI起始2年内完成Penn关节痛老化量表,由培训评估者从病历提取依从性数据,用Cox比例风险分析老化感知与非依从时间的关系并校正关节痛严重度。结果显示144例(28.3%)非依从,高老化感知者非依从风险更高(校正HR 1.71;95%CI 1.10-2.67;p=.02),高抑郁症状亦独立相关(校正HR 1.63;95%CI 1.03-2.59;p=.04)。

要点

  • 高老化感知与AI非依从风险升高相关(校正HR 1.71)。
  • 高抑郁症状独立关联非依从风险升高(校正HR 1.63)。
  • 干预负性老化信念与抑郁情绪或可改善AI依从性。

核心结论

  • 关节痛相关的老化感知与抑郁症状可预测乳腺癌survivor对芳香化酶抑制剂的非依从。

研究设计与样本

  • 前瞻性队列研究,纳入509例正在服用AI的I-III期乳腺癌女性,均在AI起始2年内完成Penn关节痛老化量表。
  • 依从性数据由培训评估者从病历提取,采用Cox比例风险分析老化感知与非依从时间的关系,所有分析均校正关节痛严重度。

主要发现

  • 509例参与者中144例(28.3%)为非依从。
  • 高老化感知者非依从风险高于低老化感知者(校正HR 1.71;95%CI 1.10-2.67;p=.02)。
  • 高抑郁症状亦独立关联非依从风险升高(校正HR 1.63;95%CI 1.03-2.59;p=.04)。

临床怎么用

  • 对服用AI且伴关节痛的乳腺癌survivor,可评估其老化感知与抑郁症状以识别非依从高风险者。
  • 针对AI相关关节痛所致负性老化信念及抑郁情绪的干预,可能有助于改善AI依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Aromatase inhibitors (AIs) are a potentially life-saving treatment for breast cancer survivors, yet poor adherence to treatment is a prevalent problem. A common adverse effect of AI treatment is arthralgia, which is identified by survivors as a major reason for treatment discontinuation. Women who experience arthralgia on AIs often report feeling they have aged rapidly while on the treatment. In the present study, we examined whether arthralgia-associated ageing perceptions predicted non-adherence. PATIENTS AND METHODS: We conducted a prospective cohort study among women with stage I-III breast cancer, who were on an AI and completed the Penn Arthralgia Aging Scale within 2 years of AI initiation. Adherence data were abstracted from medical charts by trained raters. Cox proportional hazard analysis was used to determine the relationship between ageing perceptions and time to non-adherence. All analyses included adjustments for joint pain severity. RESULTS: Among 509 participants, 144 (28.3%) were non-adherent. As hypothesised, women with high levels of ageing perceptions were at greater risk of non-adherence than women with low levels of ageing perceptions (adjusted hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.10-2.67; p = .02). High levels of depressive symptoms were also uniquely associated with increased risk of non-adherence (adjusted HR, 1.63; 95% CI, 1.03-2.59; p = .04). CONCLUSION: Perceptions of ageing related to arthralgia and depressive symptoms predicted non-adherence to AIs. These findings suggest that interventions that address negative beliefs about ageing due to AI-related arthralgia and depressive mood can potentially improve rates of adherence to AIs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Brier MJ, Chambless DL, Chen J, et al. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors. Eur J Cancer. 2018. PMID: 29329697. doi:10.1016/j.ejca.2017.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。